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Pactamycin, one of the most densely functionalized
aminocyclitol antibiotics, has pronounced antibacte-
rial, antitumor, antiviral, and antiplasmodial activi-
ties, but its development as a clinical drug was
hampered by its broad cytotoxicity. Efforts to modu-
late the biological activity by structural modifications
using synthetic organic chemistry have been difficult
because of the complexity of its chemical structure.
However, through extensive biosynthetic studies
and genetic engineering, we were able to produce
analogs of pactamycin that show potent antimalarial
activity, but lack significant antibacterial activity, and
are about 10–30 times less toxic than pactamycin
toward mammalian cells. The results suggest that
distinct ribosomal binding selectivity or new mecha-
nism(s) of action may be involved in their plasmodial
growth inhibition, which may lead to the discovery of
new antimalarial drugs and identification of new
molecular targets within malarial parasites.
INTRODUCTION
Pactamycin is a structurally unique antitumor antibiotic isolated
from the soil bacterium Streptomyces pactum (Bhuyan, 1962). It
shows potent antimicrobial (Bhuyan, 1962), antitumor (White,
1962), antiviral (Taber et al., 1971), and antiprotozoal (Otoguro
et al., 2010) activities, and literally affects cell growth of all three
phylogenetic domains, eukarya, bacteria, and archaea. Its
broad-spectrum growth inhibitory activity is mainly due to its
ability to bind a conserved region within the 30S ribosomal
subunit of most organisms, inhibiting the translocation of certain
mRNA-tRNA complexes and blocking protein synthesis (Bro-
dersen et al., 2000; Dinos et al., 2004). Although pactamycin
was first reported in the 1960s and its various biological activi-
ties have been extensively investigated, further development
of this compound was hampered by its wide-ranging cytotox-
icity. Moreover, its complex chemical structure has rendered
its structural modification via synthetic organic chemistry
difficult.Chemistry & Biology 18,The biosynthetic origin of pactamycin had been studied by
feeding experiments with isotopically labeled precursors (Rine-
hart et al., 1981; Weller and Rinehart, 1978). It has been
suggested that the five-member ring aminocyclitol moiety of
pactamycin is derived from glucose, whereas 6-methyl salicylic
acid (6MSA) is derived from acetic acid. The 3-aminoacetophe-
none moiety is derived from an unknown branch of the shikimate
pathway (Rinehart et al., 1981). More insights into the biosyn-
thesis of pactamycin have emerged from the recent identification
of the biosynthetic gene cluster of pactamycin in S. pactum
(Ito et al., 2009; Kudo et al., 2007). On the basis of the latter
study, it was postulated that PtmC (a radical SAM enzyme),
PtmJ (a glycosyltransferase), and PtmG (a putative deacetylase)
are involved in the formation of the cyclopentitol core (I) (Fig-
ure 1A), which is then converted to compound II through isomer-
ization and aminotransferation. However, little is known about
the mode of formation of this interesting aminocyclopentitol
core structure.
No less intriguing an aspect of pactamycin biosynthesis is its
high degree of tailoring modifications (e.g., N-carbamoylation,
N-methylation, C-methylation, hydroxylation, and 6MSA attach-
ment), which are all confined within the highly compacted core
structure (Figure 1A). Feeding experiments using 13C-methionine
revealed that five methylation events are involved in pactamycin
biosynthesis, three of which are C-methylations and two are
N-methylations (Weller and Rinehart, 1978). Most remarkably,
the C-7/C-8 hydroxyethyl moiety is derived from two units of
methionine through ‘‘tandem’’ C-methylations. C-Methylation
also occurs at the neighboring C-5 position of the core cyclopen-
titol unit. In silico analysis of the pactamycin cluster suggests
that these C-methylations may be catalyzed by radical SAM-
dependent enzymes. Similar enzymes have been proposed to
play a role in the biosynthesis of clorobiocin (Westrich et al.,
2003), fortimicin KL1 (Kuzuyama et al., 1995), fosfomycin (Hig-
gins et al., 2005), mitomycin (Mao et al., 1999), and many other
important primary and secondary metabolites (Sofia et al.,
2001). Such tailoring enzymes are certainly important from a
pharmaceutical point of view, because inactivation of these
enzymes may result in pactamycin analogs that have been
deemed difficult to obtain by synthetic organic chemistry.
Herein, we describe the functional analysis of the putative
tailoring genes in S. pactum ATCC 27456 and postulate their
roles in pactamycin biosynthesis. In addition, the study resulted
in a number of pactamycin analogs that showed potent425–431, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 425
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Figure 1. Biosynthesis of Pactamycin
(A) A synopsis of the proposed biosynthetic pathway to pactamycin is shown.
(B) The core biosynthetic gene cluster of pactamycin and the putative tailoring genes are shown.
For additional details supporting data from this figure, see Figure S1.
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Pactamycin Analogs with Antimalarial Activityantimalarial activity, but in contrast to pactamycin, have no
significant antibacterial activity and reduced cytotoxicity against
mammalian cells.
RESULTS AND DISCUSSION
Inactivation of the Carbamoyltransferase PtmB
Structurally, pactamycin consists of an aminocyclopentitol unit,
two aromatic rings, and a 1,1-dimethylurea. The ureamoietymay
be derived from N-carbamoylation of the C-1 amino group. A
gene encoding a protein with high identity to carbamoyltrans-
ferases has been identified within the pactamycin cluster and
is predicted to mediate this reaction (Ito et al., 2009). Interest-
ingly, the protein (PtmB) is more similar to carbamoyltrans-
ferases that catalyze O-carbamoylation than those that catalyze
N-carbamoylation. To investigate whether PtmB is involved in
pactamycin biosynthesis, the gene was inactivated by targeted
in-frame deletion. Analysis of the culture broth of the DptmB
strain revealed that the mutant was not able to produce pacta-
mycin, suggesting a direct involvement of ptmB in pactamycin
biosynthesis. However, no other pactamycin-related products
could be detected in the samples. Complementation experi-
ments by introducing into the DptmB strain an integrative
plasmid harboring the intact ptmB gene resulted in conjugants
that were able to produce pactamycin, albeit in low yields, elim-
inating the possibility of polar effects in the DptmB strain.426 Chemistry & Biology 18, 425–431, April 22, 2011 ª2011 ElsevierFormation of the N,N-Dimethylurea Unit
Further modification of the urea functionality to N,N-dimethy-
lurea may be catalyzed by SAM-dependent N-methyltrans-
ferases. However, because ptmD is the only N-methyltransfer-
ase gene present in the cluster, it is predicted to play a role in
both N-methylation reactions. To test this hypothesis, we inacti-
vated ptmD in S. pactum and analyzed the antibiotic production
by LC-MS. As expected, the DptmD strain was not able to pro-
duce pactamycin or 7-deoxypactamycin, but instead produced
two new metabolites with m/z 531 (M+H)+ and m/z 515 (M+H)+
(Figure 2B). MS/MS analysis of the products gave fragmentation
patterns that are consistent with those predicted for N,N-dide-
methylpactamycin and N,N-didemethyl-7-deoxypactamycin,
respectively (see Figure S2 available online), indicating that
PtmD is responsible for the N-methylations of the urea moiety.
The Roles of the Fe-S Radical SAM
C-Methyltransferases
In addition to the carbamoyltransferase PtmB and the N-methyl-
transferase PtmD, the radical SAM-dependent enzymes PtmH,
PtmL, and PtmM are believed to be involved in the decoration
of the aminocyclopentitol unit. The involvement of these
enzymes in pactamycin biosynthesis is particularly fascinating,
because they may catalyze methylation of nonreactive carbons
within a fairly crowded five-member ring structure. Moreover,
one of the enzymes was predicted to catalyze methylation ofLtd All rights reserved
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Figure 2. Partial Mass Spectra of the Ethyl Acetate Extracts Obtained from the Culture Broths of the Wild-Type and the Mutant Strains of
S. pactum
(A–E) Wild-type (A), DptmD (B), DptmH (C), DptmQ (D), and DptmH/DptmQ (E) strains are shown. Thick arrows indicate positions at which modifications take
place. For additional experiments supporting data from this figure, see Figures S2–S4.
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Pactamycin Analogs with Antimalarial Activitya methyl group (C-7), which itself is derived from methionine
involving another radical SAM C-methyltransferase enzyme.
These tandem methylations result in an ethyl moiety, which is
then hydroxylated to form the hydroxyethyl side chain.
To explore the roles of those enzymes in pactamycin biosyn-
thesis, we inactivated the genes individually and examined their
phenotypes. LC-MS analysis of the culture broths of the mutants
revealed the lack of pactamycin production in those strains,
suggesting the involvement of ptmH, ptmL, and ptmM in pacta-
mycin biosynthesis. Although DptmL and DptmM did not give
any detectable amount of pactamycin or its analogs, DptmH
produced a new compound with m/z 529 [M+H]+ (Figure 2C).
On the basis of 1D and 2D NMR and MS/MS analyses (Figures
S2 and S3), the compound was determined to be 7-demethyl-
7-deoxypactamycin (TM-026). The results suggest that PtmH
is involved in the formation of the hydroxyethyl unit and that
hydroxylation occurs after the second methylation. PtmY, which
shares high identity with cytochrome P450 monooxygenases, is
proposed to play a role in the hydroxylation reaction. However,Chemistry & Biology 18,inactivation of ptmY in S. pactum resulted in mutant strains
that not only produced 7-deoxypactamycin but also a small
amount of pactamycin (data not shown). The result thus, unfortu-
nately, did not provide solid evidence for the catalytic function of
PtmY, because both compounds are routinely found in different
ratios in the culture broths of the wild-type strain. Therefore,
either PtmY is not directly involved in the hydroxylation of C-7
or its function in DptmY strain was complemented by another
monooxygenase. On the other hand, PtmL and PtmM may
catalyze the attachment of C-6 and C-7. Inactivation of these
genes may have blocked the methylation reactions but, as in
the case of DptmB, no intermediate compounds were accumu-
lated in the culture broths or in the cells at a detectable level.
Complementation experiments by introducing expression
plasmids harboring intact ptmH, ptmL, or ptmM into the corre-
spondingmutant strains ofS. pactum showed that all conjugants
were able to produce pactamycin, suggesting that there was
no polar effect that obstructed pactamycin biosynthesis in the
mutants.425–431, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 427
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Figure 3. Antimalarial Activity of Pactamycin Analogs against the Chloroquine-Sensitive (D6) and Chloroquine-Resistant (Dd2) Strains of
Plasmodium falciparum
(A–F) Chloroquine (A), TM-025 (B), TM-026 (C), pactamycate (D), pactamycin (E), and N-acetylglucosaminyl-3-aminoacetophenone (F) are shown. All values are
presented as relative fluorescence units (RFU). Each value is mean ± SEM of quadruplicate values from a representative experiment. The 50% and 90% inhibitory
concentrations (IC50 and IC90) were determined by nonlinear regression analysis of logistic dose-response curves (GraphPad Prism software).
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Pactamycin Analogs with Antimalarial ActivityDouble Knockout of ptmH and ptmQ
Although the production of TM-026 by theDptmH strain revealed
the function of ptmH in pactamycin biosynthesis, the result was
somewhat unexpected. Previously, we had demonstrated that
inactivation of the iterative type I polyketide synthase gene
ptmQ within the cluster effectively halted the formation of
6MSA, and the mutant strain produced de-6MSA-pactamycin
and de-6MSA-pactamycate (pactamycin analogs without
6MSA) (Ito et al., 2009). The result had led us to conclude that
the attachment of 6MSA occurs last in the pathway. However,
the formation in the DptmH strain of TM-026 that lacks a methyl
and a hydroxy group yet retains the 6MSA moiety suggests
otherwise. Moreover, it is also quite puzzling that the product
of the DptmD strain contains, except for the two N-methyl
groups, all other functionalities. These results suggest that
some tailoring enzymes involved in pactamycin biosynthesis
have relaxed substrate specificity. The promiscuity of some of
these enzymes not only makes the sequence or the timing of
the tailoring processes unclear, but also hinders the production
of smaller analogs of pactamycin. To generate less-decorated
pactamycin analogs, we constructed a double gene knockout
mutant, in which both ptmH and ptmQ are inactivated. As ex-
pected, mutant strains resulting from this double gene knockout
produced another new analog of pactamycin with m/z 395
[M+H]+, which, on the basis of the careful structural characteriza-
tion using 1D and 2D NMR and MS/MS analyses, was identified428 Chemistry & Biology 18, 425–431, April 22, 2011 ª2011 Elsevieras de-6MSA-7-demethyl-7-deoxypactamycin (TM-025) (Fig-
ure 2E; Figures S2 and S4).
Antimalarial Activity of TM-025 and TM-026
During our initial screening for new antimalarial natural products,
we found that de-6MSA-pactamycin demonstrated a potent
activity against both chloroquine-sensitive and -resistant strains
of Plasmodium falciparum at low nanomolar concentrations
(data not shown). However, similar to pactamycin, de-6MSA-
pactamycin also showed significant antimicrobial activity and
high cytotoxicity against mammalian cells (Ito et al., 2009).
More recently, Otoguro and co-workers reported a similar
finding, in which pactamycin and 7-deoxypactamycin showed
high activities against both the drug-resistant K1 and drug-
susceptible FCR3 strains of P. falciparum (Otoguro et al.,
2010). They noted that 7-deoxypactamycin, which lacks
a hydroxy group at C-7, was 40 timesmore active than pactamy-
cin. However, its cytotoxicity was also much higher than that of
pactamycin. The new compounds TM-025 and TM-026, which
were subjected to testing against P. falciparum D6 (chloroquine
sensitive) and Dd2 (chloroquine resistant) strains, showed
pronounced antimalarial activity with IC50 values between 25
and 30 nM against both strains, on a par with pactamycin
(Figure 3). However, the IC90 values for TM-025 and TM-026
(62–77 nM) were significantly lower than those for pactamycin
(124 and 187 nM), particularly against the Dd2 strain, indicatingLtd All rights reserved
Figure 4. Antibacterial and Cytotoxicity Assays of Pactamycin Analogs
(A–D) Agar-diffusion assay of pactamycin analogs against S. aureus (A),B. subtilis (B), P. aeruginosa (C), and E. coli (D) are shown. 1, 20 ml 10mMTM-025; 2, 20 ml
1 mM TM-025; 3, 20 ml 10 mM TM-026; 4, 20 ml 1 mM TM-026; 5, 20 ml 10 mM pactamycin; 6, 20 mL 1 mM pactamycin; 7, 20 ml 10 mM N-acetyl-glucosaminyl-3-
aminoacetophenone; 8. 5 ml 1 mg/ml ampicillin.
(E–H) Microdilution assay of pactamycin analogs against S. aureus (E),B. subtilis (F), P. aeruginosa (G), and E. coli (H) are shown. TM-025: 1 mM–10 nM; TM-026:
1 mM–10 nM; Pct (pactamycin): 0.5 mM–10 nM; Amp (ampicillin): 10 mg/ml–0.1 mg/ml; Apra (apramycin): 5 mg/ml–50 ng/ml; NC, negative control. Molar
concentrations were used for pactamycin analogs to reflect more accurate comparisons between those compounds.
(I–J) Cytotoxicity assay of pactamycin analogs against HCT116 cells using broad-range concentrations at 48 hr (I), narrow-range concentrations at 24 hr (J), and
narrow-range concentrations at 48 hr (K). Blue triangles represent pactamycin, black circles represent TM-025, red squares represent TM-026, and green
triangles represent N-acetyl-glucosaminyl-3-aminoacetophenone. All values are presented as percentage of viable cells, which was calculated relative to the no
treatment and solvent only wells. Each value is mean ± SEM of triplicate values from a representative experiment.
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Pactamycin Analogs with Antimalarial Activitysome superiority of the new analogs in their antimalarial activity
over the parent compound. The results also suggest a possible
acquired resistance within the parasites against pactamycin
(Figure 3E). As a comparison, the less active analog pactamy-
cate showed IC50 and IC90 values at around 300 nM and
800 nM, respectively, against both strains. Moreover, the inhib-
itory patterns of TM-025 and TM-026 appeared to be somewhat
different from that of pactamycin, which suggests that the new
analogs may inhibit plasmodial growth via a distinct mechanism
of action. The putative pactamycin biosynthetic precursor
N-acetylglucosaminyl-3-aminoacetophenone was also tested,
and its lack of activity suggests that the antimalarial activity is
not due to the aminoacetophenone moiety.
Antibacterial Activity of TM-025 and TM-026
Most surprising results emerged from the antibacterial assays.
Although pactamycin demonstrates a strong antibacterialChemistry & Biology 18,activity against both Gram-positive and -negative bacteria,
neither TM-025 nor TM-026 showed any significant activity in
the agar diffusion andmicrodilution assays at the concentrations
used (Figures 4A–4H). The IC50 values of pactamycin were
about 10 mM against Staphylococcus aureus, 500 mM against
Pseudomonas aeruginosa and Bacillus subtilis, and 100 mM
against Escherichia coli, whereas the IC50 values of TM-025
and TM-026 were consistently higher (mostly >1 mM) against
all tested bacterial strains. The results suggest that the new
analogs have less affinity to the bacterial ribosome or interact
with it in a less damaging fashion than pactamycin.
Cytotoxic Activity of TM-025 and TM-026
To determine the effect of TM-025 and TM-026 on mammalian
cells, their cytotoxic activity was evaluated and compared to
that of pactamycin in a WST-8–based assay using HCT116
human colorectal cancer cells. The results revealed that the425–431, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 429
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Pactamycin Analogs with Antimalarial Activitynew analogs are significantly less toxic than pactamycin, with
estimated IC50 values between 1000 and 3000 nM, or about
10–30 times higher than that of pactamycin (IC50 100 nM)
(Figures 4I–4K). The results support the notion that the new
analogs have less affinity toward the ribosome of mammalian
cells, or their antimalarial activity is the result of a different mech-
anism of action. Further work is currently under way to determine
the structure-activity relationship of this untapped class of
natural products and to unveil their mechanism(s) of action
against plasmodium parasites.SIGNIFICANCE
Pactamycin is one of the most densely functionalized ami-
nocyclitol antibiotics, with pronounced biological activities.
Literally, it affects cell growth of all three phylogenetic
domains; therefore, despite its potent biological activity, it
was not considered to be a viable drug lead. However, the
identification of the pactamycin cluster and the develop-
ment of gene inactivation methodologies in Streptomyces
pactum in our laboratory have made it possible for us to
investigate the biosynthesis of pactamycin at the molecular
level and to employ genetic engineering technologies to
produce analogs with improved biological properties. The
data presented here highlight the importance of biosynthet-
ically based structure modification methodologies in gener-
ating pactamycin analogs that have been deemed inacces-
sible by synthetic organic chemistry. The analogs are
structurally less complex and more stable than pactamycin
and show potent antimalarial activity, but, in contrast to
pactamycin, have significantly reduced antibacterial activity
and cytotoxicity against mammalian cells. The results
suggest that the compounds either have higher selectivity
toward the plasmodial ribosome, or new mechanism(s) of
action in plasmodial growth inhibition are involved, which
could lead to a new direction in the discovery and develop-
ment of drugs against malaria and other life-threatening
protozoal infections.EXPERIMENTAL PROCEDURES
Bacterial strains (Table S1), plasmids (Table S1), primers (Table S2), general
DNA manipulations, complementation experiments, compound purification,
structure elucidations, and biological assays are described in Supplemental
Experimental Procedures.
Construction of the ptmB, ptmD, ptmH, ptmL, ptmM, ptmY,
and ptmH/ptmQ Knockout Mutants
Two1 kb PCR fragments upstream and downstream of the geneswere fused
and cloned into the HindIII/XbaI site of pBluescript II SK(-) vector. For ptmB,
the products were subsequently excised with HindIII and XbaI, treated with
Klenow enzyme, and ligated into pTMW018 (predigested with BamHI and
treated with Klenow enzyme) to create pTMW025 (Table S1). For ptmD,
ptmH, ptmL, ptmM, and ptmY, the products were excised and cloned into
the HindIII/XbaI site of pTMN002 to create pTMN003, pTMW026, pTMW027,
pTMN004, and pTMN005, respectively. All plasmids were then individually
introduced into S. pactum ATCC 27456 by conjugation using the E. coli donor
strain ET12567/pUZ8002. For ptmH/ptmQ mutant, the plasmid pTMN001 (Ito
et al., 2009) was transferred into E. coli ET12567/pUZ8002 and subsequently
was introduced into the DptmH strain by conjugation. Screening and analysis
of the mutants were performed as described elsewhere (Ito et al., 2009).430 Chemistry & Biology 18, 425–431, April 22, 2011 ª2011 ElsevierAnalysis of Metabolites from the ptmB, ptmD, ptmH, ptmL, ptmM,
ptmY, and ptmH/ptmQ mutants
Themutant strains of S. pactumwere cultured inmodified Bennetmedium and
the products were extracted and analyzed as described in Supplemental
Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.chembiol.2011.01.016.
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